The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

On the post-earnings call with analysts, Chief Executive Andrew Witty addressed the recent public backlash over high drug costs and transparency of coverage, particularly following killing of Brian ...